SCHEMBL20325468

SCHEMBL20325468

CN1CCN(CCCCCCOCCN2CCN(CCCN3CCN(C)CC3)CC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
USP2 O75604 1/20 0.49
HPGD P15428 1/20 0.49
PAOX Q6QHF9 1/20 0.48
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GNAI3 P08754 1/20 0.43
GNAO1 P09471 1/20 0.43
GNAI1 P63096 1/20 0.43
RAB9A P51151 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
CSNK2A3 Q8NEV1 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
POLB P06746 1/20 0.39
RAD52 P43351 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24921696 0.88 ALDH1A1 (0.44) ALDH1A1USP2HPGDPAOXKDM4E
SCHEMBL24920416 0.88 ALDH1A1 (0.46) ALDH1A1USP2HPGDPAOXKDM4E
SCHEMBL19634433 0.88 GNAI3 (0.53) ALDH1A1USP2HPGDPAOXKDM4E
SCHEMBL24920414 0.88 ALDH1A1 (0.44) ALDH1A1USP2HPGDPAOXKDM4E
SCHEMBL2512123 0.87 ALDH1A1 (0.55) ALDH1A1USP2HPGDPAOXKDM4E
SCHEMBL21673581 0.86 ALDH1A1 (0.46) ALDH1A1USP2HPGDPAOXKDM4E
SCHEMBL23471047 0.86 GNAI3 (0.50) ALDH1A1USP2HPGDKDM4EMEN1
SCHEMBL20234239 0.86 ALDH1A1 (0.47) ALDH1A1USP2HPGDPAOXKDM4E
SCHEMBL20234243 0.86 ALDH1A1 (0.45) ALDH1A1USP2HPGDPAOXKDM4E
SCHEMBL23205258 0.84 GNAI3 (0.49) ALDH1A1USP2HPGDKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2020-07-28 US disclosed
US-10604506-B2 Modulators of estrogen receptor proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2020-03-31 US disclosed
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2020-02-06 US disclosed
US-20180179183-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES ARVINAS OPERATIONS, INC. 2018-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179183-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, ARAF, VHL ALDH1A1 2833/4885USP2 29/4885HPGD 4053/4885
US-10604506-B2 Modulators of estrogen receptor proteolysis and associated methods of use ADRM1, MDM2, ESR2 ALDH1A1 2935/4885USP2 19/4885HPGD 3052/4885
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, BRAP, VHL ALDH1A1 3773/4885USP2 180/4885HPGD 4163/4885
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL ALDH1A1 2833/4885USP2 29/4885HPGD 4053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.